再次血运重建率在西罗莫司和紫杉醇的两个临床试验类似，分别为5.6%和5.3%。
Revascularization rates were similar with the sirolimus - and paclitaxel-eluting stents in the two trials, at 5.6% versus 5.3%, respectively.
Kushwaha和他的同事试验西罗莫司作为可选择的抗增值免疫抑制药物的使用。
Kushwaha and colleagues tested the use of sirolimus as an alternative anti-proliferative immunosuppressant drug.
这项先导试验是设计用来评估西罗莫司用于肾功不全肝移植受体的安全性和有效性的。
This pilot trial was designed to assess the safety and efficacy of SRL in liver transplant recipients with renal dysfunction.
在临床试验注册网站查询未公布的试验数据，对上交到美国食品与药物管理局的与福莫特罗有关的资料也进行查证。
Web sites of clinical trial registers were checked for unpublished trial data and Food and Drug Administration submissions in relation to formoterol were also checked.
他克莫司治疗克罗恩病瘘管患者：一项随机，安慰剂对照试验。
Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial.
他克莫司治疗克罗恩病瘘管患者：一项随机，安慰剂对照试验。
Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial.
应用推荐